BACKGROUND: Despite the high prevalence of complementary and alternative medicine (CAM) product useamong the elderly, little is known about the extent of concurrent CAM-eonventional medicine use and the potential for adverse reactions.
The use of complementary and alternative medicine (CAM) products retnains prevalent in the US population. TheSlone survey (random survey of the Uspopulation)found that about half of those surveyed (n =2590) took a preJCription drug in the previous week and 16% of these prescription drug usersalso took one or more CAM supplements during the survey week.' Among those oVer the age of 65 years, the Slone survey alsoshowedthat 23% of womenand 12% of men had used 5 or more medications in the previous week.Of these, 14% hadused herbal treatments in additionto sUpplements, prescription drugs,and other over-the-counter drugs during the survey week.Despitethe high prevalence of CAMproduct use, little is known about theextentof concomitantuse of specific CAMs with conventional medicines or the potential for adverse reactions from these combinations. The elderly are of special concernbecausepolypharmacy is Well documented, sensitivity to some tnedications is greater, and the organs that rocess many drugs become less functIonal as people age. These factors raise thelikelihood that potentially toxic drug combinations will occur. Of further concern, it is generally recognized that abouthalf of herbal product users do not discuss their usẽ i th a healthcare professional, creating a theoretically signifIcant riskfor adverse CAM product-drug interactions.
In this study, we reviewed the literature to assessthe risk ofCombining various CAM medications with conventional llledications. We determined the prevalence of the most
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common CAM product and conventional drug combinations and identified those that have the potential for adverse interactions.
Methods
The study, Race and HerbalMedications AmongMedicare Recipients (RHM),was approved by the University of Washington's Institutional Review Board. Research involved analysis of secondary data originally collected as part of the Cardiovascular Health Study (CHS). CHS was a 10 year, prospective, population-based cohort study of riskfactors for coronary heart disease andstroke in adults aged 65 years and older. The study andparticipating sites havebeen described.' At each annual clinic examination and interview, CHS participants were asked to bring all prescription medications taken in the previous 2 weeks.Participants provided the interviewers with the medication containers. The interviewertranscribed from the label the drug name, strength, and dosing instructions. Afterthe transcription process, the interviewer inquired how often the medication had been taken duringthe previous 2 weeks. Directquestions about the use of aspirin were also asked at each examination. Psatyet al.' described these methods in detail.
Five years into the CHS project, data collection was expanded to include nonprescription medications. Participants were asked to bring their nonprescription as well as their prescription drugs to the clinicexamination for interviewer transcription. Unlike the protocol for prescription medications, dosing information was not collected for nonprescription products. For RHMsummary analyses, we categorized nonprescription medications intoCAM products, vitamins, minerals,or other over-the-counter (OTC) drugs. CAMproducts weredefined as herbal (botanical) products or nonbotanical dietary supplements (eg,glucosamine) excluding vitamins and minerals. A smallfraction (0.16%) of the nonprescription agents could notbe characterized.
The RHM analysis used the medication data from 4 CHS annual examinations: (1) the fourth follow-up examination (1993) (1994) , the first year that nonprescription drugs were includedin the examination), (2) the fifth follow-upexamination (1994) (1995) , (3) the seventhfollowup examination (1996) (1997) , and (4) the ninth follow-up examination (1998) (1999) . Nearly all CHS participants wereeitherwhiteor African American. The 39 (0.8%) participants of other races wereexcluded from this analysis to allow for comparisons by race.
The dataset was prepared by listing the use of CAM products with all prescription medications and specific OTC products. Tables produced from these data were manually reviewed for potential harmful interactions, based on the published literature, by one of the authors (GWE) who has researchexperience in the area of CAM product-drug interactions. Only CAM/prescription, analgesic,or cold medication productcombinations used by 2 or more participants wereconsidered. Assessment of interactionrisk was basedon a systematic review of the primary literature,recent reviews, 4 monographic databases.t" one of which" is updated daily, and our own work.A literature search for reported adverse interactions for each CAM product that was used concurrently with a conventional medicine was conducted. Assignment of risk was qualitative, based primarily on in vivo studies in humans or on case reports.Risks of combinations were qualitatively assignedinto 1 of the following 3 categories.
NONEOR INFORMATION LACKING
Propertiesof the CAM product do not suggest a problem with the combination used. No appropriate reports of interactions between the CAM product and the conventional medicine (or drug class) werefound in the literature.
THEORETICAL
One or moreisolated case reports of adverse interactions with the conventional medicine used (or drug class) were published or thepharmacologic properties of theCAMproductpredict a potential interaction. TheCAMproduct causality wasnotobvious from a review of theliterature.
SIGNIFICANT
Reasonable evidenceexists of a specific CAM product beingcausal in a reported adverse drug interaction or clinical studies demonstrate a significant potential for an adverse interaction. In some cases, interaction potential was listedas significant when the CAM-drug combination involved both havingproperties that, when combined, had a significant chancefor an adverse interaction. For example, the combination of pentoxifylline and ginkgo was determined to have a significant risk for bleedingeven though an adverse interaction has not been well documented. Potential interactions assessed as significant were listed as pharmacodynamic interactions (additive or subtractive pharmacologic properties) or pharmacokinetic interactions (effects on absorption, distribution, metabolism, or excretion).
Simple descriptive statistics were used to show the use of medications in each time period. Differences in the prevalence of use of selected CAM substances between African American and white participants were examined usingX 2 tests.
Results
The study population consisted of 5052 CHS participants who had at least one annual medication interview during the 4 time periods of the study (1994, 1995, 1997, 1999 ); a totalof 16,173 interviews wereconducted. Participants ranged in age from 65 to 102years (median age 75 y at the 1994examination). There were 3043 (60.2%) female,2009 (39.8%) male, 838 (16.6%) African American, and 4214 (83.4%) whiteparticipants. In the 4 time periods of the drug and CAM survey, over 89% of the subjects were taking a prescription drug (Table 1) . CAM product use increased during the study period. At the start of the survey, about 6% of participants were using CAM products,while at the end, use was 15%.
The most commonCAM products used by participants in our study (Table2) were generally similar to those re-
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POrted recently from the Slone survey' and a report by Blumenthal,' with garlic, ginkgo, and ginseng in the top 7 most commonly used products. Some differences in use of individual CAM products between African Americans and Whitesin the study were evident. Among the 7 most popular CAM products, African American study participants Used significantly more garlic (p = 0.003) and cod liver oiVfishoil (p < 0.001) and less glucosamine and lecithin (p < 0.001 for both). There was not a significant difference between African Americans and whites in the use of ginseng, gingko, or coenzyme QlO at the p less than O.D1level. Table 3 shows combinations of CAM and conventional drugs used by the subjects that are considered to have significant potential for adverse consequences.v-" Of the 5052 study participants, 294 (5.8%) took combinations considered to have a significant risk for an adverse interaction. Among the 16,173 interviews conducted, there were 393 (2.4%) observed instances of these combinations. The most common 
Discussion
This study may be the first population-based analysis of the prevalence of concurrent CAM medication-conventional medicationcombinations with an evaluation of the risk of adverse interactions for individual combinations. Both CAM-OTC combinations and CAM-prescription drug combinations were evaluated.The study participants were an older population (~65 y) on Medicareand almost all (>89%) were taking at least one prescription product. CAM use increased from 6% at the beginning to about 15% at the end of the study. This prevalenceis consistent with that found for CAM productuse in the general population by the Slone survey' (14%) and a survey by Tindle et al. 24 (19%). Many CAM product-prescription drug or CAM product-OTC drug combinations were identified, with 14.4% of participants takinga CAM producttogether with a conventional medication.
Some of these combinations were consideredto have a risk for an adverse interaction. Individuals takingcombinations considered to havea significant adverse interaction risk numbered294 (5.8%),with garlicor ginkgocombinations 
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with drugs affecting bloodcoagulation, suchas aspirin, representing over 95% of the list of significant interactions. This reflects the high prevalence of use of these 2 herbal supplements and theirdescribed risks for bleeding.r" Several other observed CAM product-drugcombinations wereconsidered potentially dangerous. The highest risk combinations were judged to be the combination of garlic or ginkgo with warfarin, thecombination of ginseng withwarfarin, and thecom- bination of St. John's wort withdigoxin. Both warfarin and digoxin have a narrow therapeutic range,and any modulations in their concentrations can be disastrous. Garlic and ginkgocouldincrease the risk for bleeding with concurrent warfarin therapy due to the antiplatelet adhesion activities of the 2 herbals. 9 • 1l • 14 Panax quinquefolius ("American" ginseng) has been shown to induce CYP2C9and thus would havethe potential of decreasing warfarin benefit l5 ,16 because the more potentenantiomer, S-warfarin, is metabolized by this isoform. We have no information in our study as to whether participants were taking Panax quinquefolius or Panaxginseng ("Asian" ginseng). Panax ginseng apparently doesnotsignificantly affect S-warfarin clearance." Digoxin is eliminated in large part by P-glycoprotein, and St. John's wort is a strong inducer of this transporter. 19 ,20 Although studies examining the effectof ginkgo on warfarin INR values indicate a lackof influence,26,27 the number of volunteers involved was smalland CYP2C9 expression is influenced by genetic polymorphism. Larger studiesof ginkgo are needed to rule out risk. Of the more speculativeCAM product-drug interactions, 382 of786 (49%) involved the combination of a CAM product reported to have the potential to decrease coagulation with a drug that inhibited plateletadhesion, usually aspirin or an NSAID. The actual extentof risk is unknown.
Overall, mostof thelisted CAM-drug combinations with someriskfor adverse interactions wereconsidered pharmacodynamic with additive pharmacologic effects. With theexception of St.John's wort, important pharmacokinetic CAM product-drug interactions are poorly defined in humans. While manyCAM products inhibit cytochrome P450in vitro,fewhavebeen shown to broadly induce or inhibit themetabolism of concurrently administered drugs in vivo. St. John's wort is an exception, being a strong inducer of CYP3A4, CYP2El, andP-glycoprotein in vivo. 19 ,25,28 Although a strength of our studyis that participants presented all CAM products and conventional medications taken the previous 2 weeks to a study team member for recording, other desirable information was limited. We do not have information on the dosestaken,the prevalence of use duringthe evaluation period,or whether the CAM and conventional medications were taken simultaneously each day during thattime.A further limitation is that the paucity of studies to definitively define adverse CAM productdrug interactions limited our ability to accurately assign risk to many of the various combinations. Furthermore, negativeefficacy studiescontaining toxicitydata may not have been published. Although our survey was conducted in the years 1994, 1995,1997, and 1999,more recentsurveysl.7 show that the ranking of the most popular CAM productshas changed very little. Garlic, ginkgo, and ginseng remain at or near the top of the rankings. We would have liked to have evaluated clinical outcomes such as hospitalization for bleeding. Becauseof the low frequency of these events, even for patientson warfarin,our sample did not havethe powerto permitthis evaluation.
Given the equivocal evidence for efficacy and the potential risks for bleeds,the use of CAM products affecting coagulation may not be prudent in olderpatients taking conventional medications thataffect clotting. A meta-analysis of randomized trials from 1966-2000 showed only small, short-term benefits of garlicsupplements on lipidsand antiplatelet adhesion activity." Similarly, evidence for the efficacyof ginkgo forage-related dementia hasbeenmixed.JO.l 1 As of 2006,Medicare enrollees have an insurance benefit for prescription drugs that will reduce out-of-pocket costs. This subsidy may increase the use of prescription drugsby seniors. Because the use of multiple conventional medications and the cost of dealing with their adverse effects is already a significant problem," Medicare should evaluate the use of pharmaceuticals and the safetyof these conventional combinations. Having more disposable income may also lead to even more discretionary spending on CAM supplements. The already high prevalence of use of conventional medications togetherwith CAM products by this older population pointsout the importance of conducting studies to evaluate adverse interaction risks. All healthcare professionals need to be knowledgeable on the efficacy of CAM products compared with conventional medicines for the same indication.With this knowledge, they can effectively communicate to patients the optimal balance of CAM and conventional drug therapy.
Larger studies in older adults are clearly needed to quantitate the potential for adverse drug-eAM product interactions. postmarketing surveillance may also be indicated. Of highest priority is determining the risk of combining aspirin with ginkgo or garlic, because many older adults take aspirin daily to prevent stroke and emboli.' Until the results of these clinical studies are known, healthcare providers should question patients abouttheiruse of CAM products and advise caution when they are used concurrently withconventional drugs.
Conclusions
A retrospective analysis of a Medicare population revealed that concurrent use of conventional and CAM products was common. At year 4 of the study, 15.1 % of the population used CAM products, 14.4% were concurrently taking conventional medications, and 5.8% were taking combinations considered to have a significant potential risk for an adverse interaction. Most of the combinations with risk involved concurrent use of CAM products with a risk for bleeding (especially ginkgo and garlic) together withconventional drugstakento reduce bloodclotting (especially aspirin). This study revealsthe importance of undertaking studies to define the actual risk of taking garlic and ginkgowith aspirin in an olderpopulation. 
